DST-NRF Centre of Excellence for Biomedical Tuberculosis Research/South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
National Health Laboratory Services, Green Point, Cape Town, South Africa.
J Clin Microbiol. 2018 Aug 27;56(9). doi: 10.1128/JCM.00531-18. Print 2018 Sep.
Most cases of multidrug-resistant (MDR) tuberculosis (TB) are never diagnosed (328,300 of the ∼490,000 cases in 2016 were missed). The Xpert MTB/RIF assay detects resistance only to rifampin, despite ∼20% of rifampin-resistant cases being susceptible to isoniazid (a critical first-line drug). Consequently, many countries require further testing with the GenoType MTBDR assay. However, MTBDR is not recommended for use on smear-negative specimens, and thus, many specimens require culture-based drug susceptibility testing. Furthermore, MTBDR requires specialized expertise, lengthy hands-on time, and significant laboratory infrastructure and interpretation is not automated. To address these gaps, we evaluated the accuracy of the FluoroType MTBDR (FluoroType) assay. Sputa from 244 smear-positive and 204 smear-negative patients with presumptive TB (Xpert MTB positive, = 343) were tested. Culture and MTBDR on isolates served as reference standards (for active TB and MDR-TB, respectively). Sanger sequencing and MTBDR, both of which were performed on sputa, were used to resolve discrepancies. The sensitivity of FluoroType for the detection of complex was 98% (95% confidence interval [CI], 95 to 99%) and 92% (95% CI, 84 to 96%) for smear-positive and smear-negative specimens, respectively (232/237 versus 90/98 specimens; < 0.009). The sensitivity and specificity for smear-negative specimens were 100% and 97%, respectively, for rifampin resistance; 100% and 98%, respectively, for isoniazid resistance; and 100% and 100%, respectively, for MDR-TB. FluoroType identified 98%, 97%, and 97% of the , , and promoter mutations, respectively. FluoroType has excellent sensitivity with sputa equivalent to that of MTBDR with the isolates and can provide rapid drug susceptibility testing for rifampin and isoniazid. In addition, the capacity of FluoroType to simultaneously identify virtually all mutations in the , , and promoter may be useful for individualized treatment regimens.
大多数耐多药结核病(TB)病例从未被诊断出来(2016 年约有 49 万例,其中 32.83 万例被漏诊)。Xpert MTB/RIF 检测仅能检测到利福平耐药性,而约 20%的利福平耐药病例对异烟肼敏感(这是一种关键的一线药物)。因此,许多国家需要使用 GenoType MTBDR 检测进行进一步检测。然而,MTBDR 不建议用于痰涂片阴性标本,因此许多标本需要进行基于培养的药物敏感性检测。此外,MTBDR 需要专门的专业知识、长时间的实践经验,并且实验室基础设施要求较高,并且其解释不能自动化。为了解决这些差距,我们评估了 FluoroType MTBDR(FluoroType)检测的准确性。对 244 例痰涂片阳性和 204 例痰涂片阴性疑似结核病(Xpert MTB 阳性, = 343)患者的痰液进行了检测。培养物和 MTBDR 作为分离物的参考标准(分别用于活动性结核病和耐多药结核病)。痰液上进行的 Sanger 测序和 MTBDR 均用于解决差异。FluoroType 检测复杂型的敏感性分别为 98%(95%置信区间[CI],95%至 99%)和 92%(95%CI,84%至 96%),用于痰涂片阳性和阴性标本(232/237 与 90/98 标本; < 0.009)。对于痰涂片阴性标本,利福平耐药的敏感性和特异性分别为 100%和 97%,异烟肼耐药分别为 100%和 98%,耐多药结核病分别为 100%和 100%。FluoroType 分别鉴定出 、 和 启动子突变的 98%、97%和 97%。FluoroType 对痰液的敏感性与分离物的 MTBDR 相当,可快速提供利福平和异烟肼的药物敏感性检测。此外,FluoroType 同时鉴定 、 和 启动子中几乎所有突变的能力可能有助于个体化治疗方案。